ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
Clinical evaluation of tuberculosis viability microscopy for assessing treatment response.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Performance evaluation of alternative bacteriological measures of response to MDR/RR-TB therapy during the initial 16 weeks of treatment.BMC infectious diseases · 2025Article
- Assessing Infectiousness and the Impact of Effective Treatment to Guide Isolation Recommendations for People With Pulmonary Tuberculosis.The Journal of infectious diseases · 2025Review
- Advancing the fight against tuberculosis: integrating innovation and public health in diagnosis, treatment, vaccine development, and implementation science.Frontiers in medicine · 2025Review
- New Insights into Biomarkers for Evaluating Therapy Efficacy in Pulmonary Tuberculosis: A Narrative Review.Infectious diseases and therapy · 2023Review
- Article
- An optimized method for purifying, detecting and quantifying Mycobacterium tuberculosis RNA from sputum for monitoring treatment response in TB patients.Scientific reports · 2022Article
- Review and Updates on the Diagnosis of Tuberculosis.Journal of clinical medicine · 2022Review
- Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa.Frontiers in immunology · 2021Article
- Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study.The European respiratory journal · 2020Article
- A Novel Biocompatible Titanium-Gadolinium Quantum Dot as a Bacterial Detecting Agent with High Antibacterial Activity.Nanomaterials (Basel, Switzerland) · 2020Article
- Testing the Competence ofThe American journal of tropical medicine and hygiene · 2019Article
- Sputum smear microscopy in the XpertThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2019Article
- Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis.PloS one · 2019Article
- Pulmonary Tuberculosis Conversion Documented by Microscopic Staining for Detection of Dynamic, Dormant, and Dead Mycobacteria (DDD Staining).Journal of clinical microbiology · 2018Article
- Rapid and specific labeling of single liveScience translational medicine · 2018Article
- The Potential for Testing Stool to Reduce Tuberculosis Missed Diagnoses and Misdiagnoses.The American journal of tropical medicine and hygiene · 2018Article
- Article
- Rapid detection ofScience translational medicine · 2018Article
- A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study.The Lancet. Infectious diseases · 2017Article
- Sputum Microscopy With Fluorescein Diacetate Predicts Tuberculosis Infectiousness.The Journal of infectious diseases · 2017Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundIt is difficult to determine whether early tuberculosis treatment is effective in reducing the infectiousness of patients' sputum, because culture takes weeks and conventional acid-fast sputum microscopy and molecular tests cannot differentiate live from dead tuberculosis.
methodsTo assess treatment response, sputum samples (n=124) from unselected patients (n=35) with sputum microscopy-positive tuberculosis were tested pretreatment and after 3, 6, and 9 days of empiric first-line therapy. Tuberculosis quantitative viability microscopy with fluorescein diacetate, quantitative culture, and acid-fast auramine microscopy were all performed in triplicate.
resultsTuberculosis quantitative viability microscopy predicted quantitative culture results such that 76% of results agreed within ±1 logarithm (rS=0.85; P<.0001). In 31 patients with non-multidrug-resistant (MDR) tuberculosis, viability and quantitative culture results approximately halved (both 0.27 log reduction, P<.001) daily. For patients with non-MDR tuberculosis and available data, by treatment day 9 there was a >10-fold reduction in viability in 100% (24/24) of cases and quantitative culture in 95% (19/20) of cases. Four other patients subsequently found to have MDR tuberculosis had no significant changes in viability (P=.4) or quantitative culture (P=.6) results during early treatment. The change in viability and quantitative culture results during early treatment differed significantly between patients with non-MDR tuberculosis and those with MDR tuberculosis (both P<.001). Acid-fast microscopy results changed little during early treatment, and this change was similar for non-MDR tuberculosis vs MDR tuberculosis (P=.6).
conclusionsTuberculosis quantitative viability microscopy is a simple test that within 1 hour predicted quantitative culture results that became available weeks later, rapidly indicating whether patients were responding to tuberculosis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.